2
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
UNKNOWN
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
76
Polycystic Ovary Syndrome
3
Neoplasms, Hormone-Dependent
3
Neoplasm Metastasis
3
Arthralgia
3
Advanced Breast Cancer
3
Osteoporosis
2
Fractures, Bone
2
Endometrial Neoplasms
2
Carcinoma, Lobular
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Ductal, Breast
2
Breast Diseases
2
Breast Cancer Female
2
Sexuality
1
Sexual Dysfunctions, Psychological
1
Neurotoxicity Syndromes
1
Luminal B/HER2-negative Breast Cancer
1
Leiomyoma
1
Infertility
1
Hot Flashes
1
Hormone-receptor-positive Breast Cancer
1
Hormone Receptor Positive Breast Carcinoma
1
Hormone Receptor Positive Advanced Breast Cancer
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Fatigue
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Interventions
palbociclib
1
Vinorelbine
1
Fulvestrant
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hormone Receptor Positive Advanced Breast Cancer
×
Aromatase Inhibitors
×
Clear all
NCT05000736
2022-04-29
CAPACITY
ChineseAMS
Unknown
600 enrolled